The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells. Issue 10 (11th July 2019)

• Record Type: Journal Article
• Authors: Abazid, Alexander; Martin, Benedikt; Choinowski, Anja; McNeill, Rhiannon V.; Brandenburg, Lars‐Ove; Ziegler, Patrick; Zimmermann, Uwe; Burchardt, Martin; Erb, Holger; Stope, Matthias B.
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 10(2019)
• Page Start: 16711
• Page End: 16722
• Publication Date: 2019-07-11
• Subjects: chemotherapy -- enzalutamide -- heat shock protein -- molecular mode of action -- prostate cancer -- steroid receptor; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.28929
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Enzalutamide's accepted mode of action is by targeting the androgen receptor's (AR) activity. In clinical practice, enzalutamide demonstrates a good benefit‐risk profile for the treatment of advanced prostate cancer (PC), even after poor response to standard antihormonal treatment. However, since both, well‐established antiandrogens and enzalutamide, target AR functionality, we hypothesized that additional unknown mechanisms might be responsible for enzalutamide's superior anticancer activity. In the current study, PC cells were incubated with enzalutamide and enzalutamide‐dependent modulation of apoptotic mechanisms were assessed via Western blot analysis, TDT‐mediated dUTP‐biotin nick end‐labeling assay, and nuclear morphology assay. Alterations of heat shock protein (HSP), AR, and estrogen receptor (ER) expression were examined by Western blot analysis. Enzalutamide attenuated the proliferation of PC cells in a time‐ and dose‐dependent manner. In the presence of enzalutamide, apoptosis occurred which was shown by increased BAX expression, decreased Bcl‐2 expression, nuclear pyknosis, and genomic DNA fragmentation. Moreover, enzalutamide inhibited the expression of HSPs primarily involved in steroid receptor stabilization and suppressed AR and ERβ1 expression. This study demonstrates for the first time that enzalutamide treatment of PC cells triggers varying molecular mechanisms resulting in antiproliferative effects of the drug. In addition to the well‐characterized antagonistic inhibition of AR functionality, we have shown that enzalutamide also affects the intracellular synthesis of steroid receptor‐associated HSPs, thereby diminishing the expression of AR and ERβ1 proteins and inducing apoptotic pathways. According to an indirect attenuation of HSP‐associated factors such as steroid receptors, endometrial carcinoma, uterine leiomyosarcoma, and mamma carcinoma cells also demonstrated inhibited cell growth in the presence of enzalutamide. Our data, therefore, suggest that enzalutamide's high efficacy is at least partially independent of AR and p53 protein expression, which are frequently lost in advanced PC. Abstract : In this manuscript, we present a study that demonstrates for the first time that enzalutamide treatment of prostate cancer (PC) cells trigger varying growth‐inhibitory mechanisms. In addition to the well‐characterized antagonistic inhibition of androgen receptor's (AR) functionality, we have shown that enzalutamide also affects the intracellular synthesis of steroid receptor‐associated heat shock proteins, thereby diminishing the expression of AR and estrogen receptor β1 proteins and inducing apoptotic pathways. Our data, therefore, suggest that enzalutamide's high efficacy is at least partially independent of AR and p53 protein expression, which are frequently lost in advanced PC.